Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.49 |
| ▸ | ESR1 | P03372 | 3/20 | 0.48 |
| ▸ | ESR2 | Q92731 | 3/20 | 0.48 |
| ▸ | LTA4H | P09960 | 7/20 | 0.48 |
| ▸ | PSMB1 | P20618 | 5/20 | 0.48 |
| ▸ | PSMB5 | P28074 | 5/20 | 0.48 |
| ▸ | PSMB2 | P49721 | 3/20 | 0.48 |
| ▸ | POLB | P06746 | 1/20 | 0.48 |
| ▸ | MAPT | P10636 | 1/20 | 0.48 |
| ▸ | PTGS2 | P35354 | 3/20 | 0.47 |
| ▸ | PTGS1 | P23219 | 1/20 | 0.47 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL7650467 | 0.90 | KDM4E (0.57) | KDM4EESR1ESR2LTA4HPSMB1 | |
| SCHEMBL7778580 | 0.89 | LTA4H (0.53) | ESR1LTA4HPSMB1PSMB5PSMB2 | |
| SCHEMBL3130426 | 0.86 | LTA4H (0.52) | ESR1ESR2LTA4HPSMB1PSMB5 | |
| SCHEMBL7777295 | 0.85 | LTA4H (0.53) | ESR1ESR2LTA4HPSMB1PSMB5 | |
| SCHEMBL7212312 | 0.84 | PSMB1 (0.49) | KDM4ELTA4HPSMB1PSMB5PSMB2 | |
| SCHEMBL7466056 | 0.83 | LTA4H (0.61) | KDM4ELTA4H | |
| SCHEMBL7505643 | 0.81 | SMN1; SMN2 (0.47) | KDM4EESR1ESR2LTA4HPOLB | |
| SCHEMBL7441879 | 0.76 | TDP1 (0.52) | KDM4EESR1ESR2 | |
| SCHEMBL7926826 | 0.75 | LTA4H (0.45) | KDM4EESR1LTA4HPSMB1PSMB5 | |
| SCHEMBL7918786 | 0.74 | LTA4H (0.47) | KDM4ELTA4HPSMB1PSMB5PSMB2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 21 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1204655-A2 | A CRYSTALLINE FORM OF 6-HYDROXY-3-(4-[2-(PIPERIDIN-1-YL)ETHOXY] PHENOXY)-2-(4-METHOXYPHENYL)BENZO[B]THIOPHENE HYDROCHLORIDE | ELI LILLY AND COMPANY (US) | 2002-05-15 | — | — | EP | claimed |
| EP-1121125-A1 | PHARMACEUTICAL FORMULATIONS FOR USE IN ESTROGEN DEPRIVATION SYNDROME | ELI LILLY AND COMPANY (US) | 2001-08-08 | — | — | EP | claimed |
| US-6258826-B1 | HALOGEN SUBSTITUTED BENZOTHIOPHENE COMPOUNDS WITH CARRIERS | ELI LILLY AND COMPANY | 2001-07-10 | — | — | US | claimed |
| WO-2001009115-A2 | A NOVEL CRYSTALLINE FORM OF 6-HYDROXY-3- (4-[2-(PIPERIDIN-1- YL)ETHOXY] PHENOXY)-2- (4-METHOXYPHENYL) BENZO[b]THIOPHENE HYDROCHLORIDE | ELI LILLY AND COMPANY (US) | 2001-02-08 | — | — | WO | claimed |
| WO-2000021535-A1 | PHARMACEUTICAL FORMULATIONS FOR USE IN ESTROGEN DEPRIVATION SYNDROME | ELI LILLY AND COMPANY (US) | 2000-04-20 | — | — | WO | claimed |
| WO-2001085147-A3 | STABILIZED FORMULATIONS OF 6-HYDROXY-3-(4-[2-(PIPERIDIN-1-YL) ETHOXY]PHENOXY)-2-(4-METHOXYPHENYL) BENZO[b]THIOPHENE AND SALTS THEREOF | LILLY CO ELI (US) | 2003-08-28 | — | — | WO | disclosed |
| EP-1328521-A2 | A CRYSTALLINE FORM OF 6-HYDROXY-3-(4-[2-(PIPERIDIN-1-YL)ETHOXY]PHENOXY)-2-(4-METHOXYPHENYL)BENZO[B]THIOPHENE HYDROCHLORIDE | ELI LILLY AND COMPANY (US) | 2003-07-23 | — | — | EP | disclosed |
| US-20020198179-A1 | Selective estrogen receptor modulators in combination with estrogens | ENDORECHERCHE, INC. | 2002-12-26 | — | — | US | disclosed |
| EP-1251855-A1 | SELECTIVE ESTROGEN RECEPTOR MODULATORS IN COMBINATION WITH ESTROGENS | Endorecherche, Inc. (CA) | 2002-10-30 | — | — | EP | disclosed |
| EP-1204655-A2 | A CRYSTALLINE FORM OF 6-HYDROXY-3-(4-[2-(PIPERIDIN-1-YL)ETHOXY] PHENOXY)-2-(4-METHOXYPHENYL)BENZO[B]THIOPHENE HYDROCHLORIDE | ELI LILLY AND COMPANY (US) | 2002-05-15 | — | — | EP | disclosed |
| EP-1204656-A2 | A CRYSTALLINE FORM OF 6-HYDROXY-3-(4-[2-(PIPERIDIN-1-YL) ETHOXY] PHENOXY)-2-(4-METHOXYPHENYL) BENZO[B]THIOPHENE HYDROCHLORIDE | ELI LILLY AND COMPANY (US) | 2002-05-15 | — | — | EP | disclosed |
| EP-1204656-A2 | A CRYSTALLINE FORM OF 6-HYDROXY-3-(4-[2-(PIPERIDIN-1-YL) ETHOXY] PHENOXY)-2-(4-METHOXYPHENYL) BENZO[B]THIOPHENE HYDROCHLORIDE | ELI LILLY AND COMPANY (US) | 2002-05-15 | — | — | EP | disclosed |
| WO-2001085147-A2 | STABILIZED FORMULATIONS OF 6-HYDROXY-3-(4-[2-(PIPERIDIN-1-YL) ETHOXY]PHENOXY)-2-(4-METHOXYPHENYL) BENZO[b]THIOPHENE AND SALTS THEREOF | ELI LILLY AND COMPANY (US) | 2001-11-15 | — | — | WO | disclosed |
| WO-2001009115-A3 | A NOVEL CRYSTALLINE FORM OF 6-HYDROXY-3- (4-[2-(PIPERIDIN-1- YL)ETHOXY] PHENOXY)-2- (4-METHOXYPHENYL) BENZO[b]THIOPHENE HYDROCHLORIDE | LILLY CO ELI (US) | 2001-08-16 | — | — | WO | disclosed |
| EP-1121125-A1 | PHARMACEUTICAL FORMULATIONS FOR USE IN ESTROGEN DEPRIVATION SYNDROME | ELI LILLY AND COMPANY (US) | 2001-08-08 | — | — | EP | disclosed |
| WO-2001054699-A1 | SELECTIVE ESTROGEN RECEPTOR MODULATORS IN COMBINATION WITH ESTROGENS | ENDORECHERCHE, INC. (CA) | 2001-08-02 | — | — | WO | disclosed |
| WO-2001009115-A2 | A NOVEL CRYSTALLINE FORM OF 6-HYDROXY-3- (4-[2-(PIPERIDIN-1- YL)ETHOXY] PHENOXY)-2- (4-METHOXYPHENYL) BENZO[b]THIOPHENE HYDROCHLORIDE | ELI LILLY AND COMPANY (US) | 2001-02-08 | — | — | WO | disclosed |
| WO-2001009115-A2 | A NOVEL CRYSTALLINE FORM OF 6-HYDROXY-3- (4-[2-(PIPERIDIN-1- YL)ETHOXY] PHENOXY)-2- (4-METHOXYPHENYL) BENZO[b]THIOPHENE HYDROCHLORIDE | ELI LILLY AND COMPANY (US) | 2001-02-08 | — | — | WO | disclosed |
| WO-2001009116-A2 | A NOVEL CRYSTALLINE FORM OF 6-HYDROXY-3- (4-[2-(PIPERIDIN-1-YL) ETHOXY]PHENOXY)- 2-(4-METHOXYPHENYL)BENZO[b]THIOPHENE HYDROCHLORIDE | ELI LILLY AND COMPANY (US) | 2001-02-08 | — | — | WO | disclosed |
| WO-2000021535-A1 | PHARMACEUTICAL FORMULATIONS FOR USE IN ESTROGEN DEPRIVATION SYNDROME | ELI LILLY AND COMPANY (US) | 2000-04-20 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20020198179-A1 | Selective estrogen receptor modulators in combination with estrogens | KISS1R, ESR1, BRCA1 | KDM4E 809/4885ESR1 2/4885ESR2 8/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.